TRUTAKNA, the first and only FDA-approved BAFF and APRIL inhibitor, achieved statistical significance in all prespecified endpoints, including eGFR change from baseline and annualized slope, and risk ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results